Form 4: Thermo Fisher EVP Sells Shares After Option Exercise

Thermo Fisher Scientific Executive Vice President Frederick M. Lowery exercised stock options and subsequently sold shares totaling 13,825 shares under a pre-arranged 10b5-1 trading plan.

Summary

• Frederick M. Lowery, Executive Vice President of Thermo Fisher Scientific Inc. (TMO), engaged in transactions involving the company's common stock.
• On December 1, 2025, Lowery exercised options to acquire 6,913 shares of common stock at an exercise price of $253.99 per share.
• Immediately following the exercise on December 1, 2025, Lowery sold 6,913 shares of common stock at a price of $597.68 per share.
• On December 2, 2025, Lowery exercised options to acquire 6,912 shares of common stock at an exercise price of $253.99 per share.
• Immediately following the exercise on December 2, 2025, Lowery sold 6,912 shares of common stock at a price of $581.94 per share.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Lowery on August 28, 2025.
• Between August 29, 2025, and December 2, 2025, Lowery also acquired 0.95 shares of TMO common stock under the company's 401(k) plan.
• The stock options exercised vested in four equal installments on February 26, 2020, 2021, 2022, and 2023, and have an expiration date of February 26, 2026.
• Following these transactions, Lowery directly beneficially owns 14,367.3724 shares of common stock, 1,175.83 shares indirectly through a 401(k) plan, and 5.036 shares indirectly through a Limited Liability Company.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions involving the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 plan. This is a common practice for executive compensation and liquidity management. While sales by insiders can sometimes be viewed negatively, the pre-planned nature mitigates concerns about market timing, making the overall sentiment neutral to slightly positive as it reflects a normal course of executive compensation.

Positives

• The transactions were conducted under a Rule 10b5-1 trading plan, indicating pre-planned activity rather than opportunistic market timing.
• The exercise of options and subsequent sale represents a liquidity event for a key executive, which is a common component of executive compensation.

Negatives

• Executive selling shares, even under a 10b5-1 plan, can sometimes be perceived as a lack of conviction by some investors, though it is a routine part of compensation management.

Future Outlook

N/A

Industry Context

N/A

Stakeholder Impact

• Shareholders: The transactions represent routine insider selling, which is a common occurrence for executives managing their compensation and personal finances. It does not directly indicate a change in the company's operational performance or strategic direction.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 reports routine insider transactions by an executive, involving the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan. Such transactions are common for executive compensation and liquidity management and do not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing.

Keywords

Thermo Fisher Scientific, TMO, Insider Transaction, Form 4, Stock Options, Executive Compensation, 10b5-1 Plan, Share Sale